Latest Articles

Publication Date
S01 E07 - Why weren't women included in clinical trials? - TVO

S01 E07 - Why weren't women included in clinical trials? TVO

Published: Nov. 11, 2025, 2 p.m.
HMI-115, a Potential First-in-Class Treatment for Endometriosis, Published Proof-of-Concept Phase II Clinical Trial Results in The Lancet Obstetrics, Gynaecology, & Women's Health - The Malaysian Reserve

HMI-115, a Potential First-in-Class Treatment for Endometriosis, Published Proof-of-Concept Phase II Clinical Trial Results in The Lancet Obstetrics, Gynaecology, & Women's Health The Malaysian Reserve

Published: Nov. 6, 2025, 8:25 p.m.
HMI-115, a Potential First-in-Class Treatment for Endometriosis, Published Proof-of-Concept Phase II Clinical Trial Results in The Lancet Obstetrics, Gynaecology, & Women's Health - Fidelity

HMI-115, a Potential First-in-Class Treatment for Endometriosis, Published Proof-of-Concept Phase II Clinical Trial Results in The Lancet Obstetrics, Gynaecology, & Women's Health Fidelity

Published: Nov. 6, 2025, 4:32 a.m.
HMI-115, a Potential First-in-Class Treatment for Endometriosis, Published Proof-of-Concept Phase II Clinical Trial Results in The Lancet Obstetrics, Gynaecology, & Women's Health - PR Newswire

HMI-115, a Potential First-in-Class Treatment for Endometriosis, Published Proof-of-Concept Phase II Clinical Trial Results in The Lancet Obstetrics, Gynaecology, & Women's Health PR Newswire

Published: Nov. 6, 2025, 4:08 a.m.
MSN Labs Gets SEC Go-Ahead to Conduct Phase IV Clinical Trial on Elagolix for Endometriosis - Medical Dialogues

MSN Labs Gets SEC Go-Ahead to Conduct Phase IV Clinical Trial on Elagolix for Endometriosis Medical Dialogues

Published: Nov. 1, 2025, 11:55 a.m.
Triple meeting 2025 – early efficacy signs for Quanta | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Triple meeting 2025 – early efficacy signs for Quanta | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Published: Oct. 27, 2025, 3:49 p.m.
ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability - Clinical Trials Arena

ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability Clinical Trials Arena

Published: Oct. 20, 2025, 1:12 p.m.
Genmab takes its Profound buy into endometrial | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Genmab takes its Profound buy into endometrial | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Published: Sept. 16, 2025, 3:39 p.m.
Endometriosis Pain Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine - Barchart.com

Endometriosis Pain Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Barchart.com

Published: Sept. 3, 2025, 3:30 p.m.
Endometrial Cancer Pipeline Outlook 2025 - Clinical Trials, - openPR.com

Endometrial Cancer Pipeline Outlook 2025 - Clinical Trials, openPR.com

Published: Aug. 20, 2025, 3:46 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!